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EBOLA VIRUS DISEASE — PATHOGENESIS,  
CLINICAL PRESENTATION AND MANAGEMENT
Abstract: On March 2014 the WHO notified the outbreak of Ebola virus disease (EVD) in Guinea, 
and infection quickly spread to another West African countries including Sierra Leone, Liberia and 
Nigeria. Current outbreak is the largest in the history, since discovery of the virus in 1976. Imported 
cases and infection among healthcare workers in Europe and United States have elucidated necessity 
of better education of medical staff. Clinicians must be familiar with clinical picture of EVD, differ-
ential diagnosis and therapeutic approach, as rapid diagnosis and prompt introduction of supportive 
therapy can have a significant impact on the survival.
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INTRODUCTION
Current outbreak of Ebola virus (EBOV) in West Africa can be described as most 
severe public health emergency in modern times [1]. The number of potential 
cases ranges from thousands to millions with mortality rate up to 74% [2]. The 
initial source of the outbreak appears to be a tiny village called Meliandou in 
southern Guinea where an index-case, a two-year old boy name Emille developed 
a haemorrhagic fever and died on 6th December 2013 [3]. On March 23, 2014, the 
World Health Organization (WHO) notified of an outbreak of EVD in Guinea [4]. 
Soon after that, the infection spread to Liberia and Sierra Leone. Imported cas-
es have occured in Nigeria, but also in European countries and USA. An unre-
lated outbreak has been reported in Democratic Republic of Congo [4]. Infection 
among healthcare workers in developed countries has showed that we are not 
properly prepare for care of patients with highly communicable diseases, and 
continuous education including clinical picture and therapy of EVD but also 
methods of isolation and use of personal protective equipment (PPE) is essential 
for safety of healthcare workers, as well as prevention of further spread of this 
danger infection [1]. 
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VIROLOGY
EBOV is zoonotic filovirus, comprised of envelope, nonsegmented negative-strand-
ed RNA. Up to now five species have been identified: Zaire ebolavirus, Bundib-
ugyo ebolavirus, Tai Forest ebolavirus (formerly known as Cote d’Ivore), Sudan 
ebolavirus, and Reston ebolavirus (found in Western Pacific, highly pathogenic in 
nonhuman primates) [5, 6]. Current West African outbreak, which is the biggest 
since the virus was discovered in 1976, is caused by Zaire ebolavirus [4]. 
Animal reservoir of the EBOV is considered to be the fruit bat. Transmission 
to humans required the contact with animal tissues or body fluids, including 
handling and ingestion of animal tissues, or ingestion of plants or water con-
taminated with bats faces or bodily fluids [7].
Occurrence of outbreak is related to human-to-human transmission. EBOV is 
usually transmitted through direct mucous membrane or percutaneous exposure 
to infected body fluids [7]. Most infectious body fluids are blood, stool and vom-
its. Virus also have been found in breast milk, urine and semen, but because 
can be detected up to 70 days these body fluids are considered to be less conta-
gious. There is no enough evidence that saliva and tears are contagious, and the 
available data are conflicted. According the WHO there is no virus in the sweat. 
EBOV can survive on the solid surface up to 6 days, so the contact with them 
can potentially cause infection [5, 7–9]. 
PATHOGENESIS
After the infection virus is disseminated within the monocytes, macrophages, den-
dritic cells to the lymph nodes, and then by blood to the spleen and liver [7, 10]. 
EBOV entry, which includes attachment and penetration into the cytoplasm, is 
mediated by the surface glycoprotein (GP) [6]. This GP is a trimeric transmem-
brane surface protein that is critical for viral attachment to the host cells, and 
could be involved at many different levels in the EBOV pathogenesis [7, 11]. GP 
serve as a decoy antigen, be involved in antigenic subversion, and play a role in re-
storing the barrier function of endothelial cells. It is suggested that GP is involved 
in neutrophils inactivation and induction of apoptosis in bystander cells [11]. 
EBOV tropism toward antigen presenting cells (APCs) seems play also an import-
ant role in viral pathogenesis [12]. The infected APCs fail to undergo maturation; 
as such they are unable to present viral antigens to naive lymphocytes. This is 
followed by massive loss of uninfected lymphocytes due to the bystander effect of 
which lymphocytes undergo massive apoptosis due to the apoptotic induction of 
inflammatory mediators or loss of support signals from dendritic cells [7, 11, 12]. 
This result in complete collapse of adaptive immune response, including limited 
range of chemokines secreted by infected cells, failed expression of costimulatory 
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molecules, failed up regulation of major histocompatibility complex (MHC), in-
ability of induced differentiation of allogenic lymphocytes [5, 7, 13]. Inhibition 
of interferon production is observed as well [7]. It was proved that patients who 
are able to develop antibodies within the second week of infection have cleared 
viremia and improved clinical symptoms. Once EBOV disseminates through the 
body, release of proinflammtory mediators and endothelial infection and dysfunc-
tion is observed. Progression of the disease is leading to the vasodilatation and 
increased vascular permeability, induction of extrinsic coagulation cascade and 
lymphocytes apoptosis [5, 7, 13]. Rasmussen et al. suggests that genetic factors 
play a significant role in determining disease outcome in naive individuals with-
out prior exposure or immunologic priming [14].
CLINICAL PRESENTATION
Incubation period for EVD is 2 to 21 days (median 2 weeks). In current outbreak 
patients with EVD presented to the hospital 3 to 7 days (median 5 days) after 
the onset of symptoms [5, 15, 16]. 
Clinical presentation of EVD is very uncharacteristic and can mimic a lot of 
tropical diseases such as malaria, typhoid fever, cholera or Lasse fever, so to es-
tablish diagnosis the epidemiological data, must be strongly taken into consider-
ation. As mentioned above EBOV is usually transmitted through direct mucous 
membrane or percutaneous exposure to infected body fluids, such as blood, stool, 
vomits, so during the history specific questions regarding the contact with any 
sick or died for Ebola individuals should be asked [5, 15, 16]. 
Initial symptoms, which usually begin abruptly, are non-specific symptoms of 
viral infections: fever, fatigue, headache, myalgia and malaise. Afterwards most 
patients are developing nausea, vomiting, anorexia, abdominal pain and diar-
rhoea. Lethargy, coughing, headache, hypotension are commonly observed. Hae-
morrhagic manifestations can vary in severity and are present in 30 to 70% of 
patients. These include maculopapular rash, mucosal haemorrhages, bleeding 
from the puncture sites, haemorrhages for gastrointestinal (GI) and genitourinary 
tract [5, 15, 16]. However, it should be stressed that in 2014 West African out-
break, number of cases with rash and other haemorrhagic complications were less 
frequent [19%], and primary clinical manifestation was gastrointestinal [2, 15]. 
In sever cases patients are developing hypovolemic shock and multiorgan failure, 
including hepatic damage, kidney and respiratory failure. Seizures and coma can 
occur as well [5, 15, 16]. Analysis of cases during the current outbreak revealed 
that most of the patients died 7 to 11 days after the onset of symptoms (median 
8 days) [15]. In previous outbreaks mortality rate range from 30 to 90%. In 2014 
in Guinea case fatality rate was 43% and in Sierra Leone 74% [2, 15]. 
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LABORATORY ABNORMALITIES AND DIAGNOSTIC PROCEDURES
Laboratory findings include leukopenia, followed by leukocytosis and atypical lym- 
phocytosis. Thrombocytopenia, as well as elevation of aminotransferases (AST 
and ALT) is a characteristic feature. Prolongation of the partial thromboplastin 
time and the international normalized ratio (INR) are common abnormality. As 
a consequence of vomiting and diarrhoea patients are developing electrolyte dis-
turbances and later metabolic abnormalities [5, 7, 9, 10, 16].
To establish diagnosis viral RNA by PCR or viral antigen by immunoenzymat-
ic methods (ELISA) should be detected in the blood or other body fluids. Rapid 
tests are available. It must be stressed that EBOV RNA can be detected 3 days 
after the infection, so in cases in which patient present to the doctor early and 
EVD is strongly suspected, the test should be repeated [5, 7, 9, 10, 16].
TREATMENT OF EBOLA VIRUS DISEASE
Currently, there is no specific treatment available for Ebola. There is also no ther-
apeutics for prevention or post exposure. Several experimental therapies are un-
der development, but not fully tested in human. However, FDA has approved some 
experimental treatments for emergency use in patients with Ebola infection [17]. 
One of them is brincidofovir — oral nucleotide analog, which is modified ver-
sion of cidofovir. In vitro data suggest its activity against Ebola and recently FDA 
approved it for Phase 2 study [17]. 
The other antiviral drug — favipiravir, previously approved in Japan for treat-
ment of flu, also showed promising results against Ebola in rodent model, but 
have to be confirmed in primates [18]. TKM Ebola and AVI 6002 are molecules 
used for blocking of viral replication genes via gene silencing. These drugs have 
shown effects against EVD in animal model but TKM Ebola’s Phase 1 study was 
partially placed in a hold status by FDA, because of signs of cytokine release in 
patients treated with high doses of this drug [17]. ZMapp is another experimental 
treatment for EVD. It contains three monoclonal antibodies, which effectiveness 
against Ebola was proven in non-human primates. In experimental study, ZMapp 
was able to revert advanced EVD in primates when treatment was initiated up 
to 5 days after infection [19]. Unfortunately, all ZMapp supplies are exhausted 
at the moment. Another experimental therapy, already used during previous Eb-
ola outbreaks, is passive immunization via convalescent whole blood and serum 
transfusion. However, the result of this method is controversial [1].
Without specific medications, treatment for Ebola is mostly limited to support-
ive care. Symptoms of EVD and its complications should be treated as they appear.
Hypovolemia due to massive fluid loss via vomiting, diarrhea and in rare cases 
vascular leak is the most common symptom of EVD. Clinical management should 
53
focus on maintaining fluid volume and correction of electrolyte abnormalities. 
It’s necessary to monitor daily fluid input and output, as well as heart rate and 
blood pressure. If tolerated, oral fluid replacement with rehydration solutions is 
preferred [16]. On the other hand, massive fluid loss needs more aggressive treat-
ment and intravenous fluid therapy [1, 16]. It is preferred to use Ringer’s solu-
tion than normal saline [20]. Because of increased risk of kidney failure, bleeding 
and mortality, colloids such as hydroxyethyl stach should be avoided [21, 22]. 
Severe electrolyte deficiencies, especially metabolic acidosis, hypokaliemia and 
hypocalcemia should also be expected. If the patient is able to eat, oral reple-
tion of electrolytes is preferred [16]. However, massive electrolyte losses require 
intravenous replacement. Following management, when used early can improve 
chances of survival. 
It was also observed that antiemetic and antidiarrheal drugs may limit mas-
sive loss of fluids via gastrointestinal tract and they should be considered [16].
Some patients may develop shock due to fluid loss, septic complications or 
bleeding. Shock is common manifestation of EVD severity and plausible lethal 
pathway [16]. This state require aggressive volume resuscitation and, when 
caused by severe blood loss, blood products transfusion. If needed, vasopressors 
such as dopamine or norepinefrine should be administered to maintain blood 
pressure. 
If disseminated intravascular coagulation develops, replacement of coagulation 
factors, correction of thrombocytopenia and anemia is necessary [1]. 
Several patients with severe EVD may develop multiorgan failure. Acute kid-
ney injury is one of the most common symptom of severe illness and it often 
needs renal replacement therapy. Liver failure, if occur, should be treated with 
supportive therapy [1]. It is also important to avoid possible nephrotoxic and 
hepatotoxic medications. On the other hand respiratory failure is more often 
secondary to other EVD complications than to primary respiratory insufficiency. 
In treatment non invasive oxygen therapy and mechanical ventilation in severe 
cases should be used [1]. 
Many patients with EVD may also have concomitant bacterial, viral or para-
site infection [10]. If coinfection cannot be excluded, specific treatment is appro-
priate. Empiric treatment with antibiotics should be considered, especially at the 
beginning of the infection when the risk of bacterial translocation form inflamed 
intestine is high [16]. However, after excluding bacterial confection, antibiotics 
should be discontinued [16]. In African countries antimalarial agents should also 
be taken into consideration [1]. 
Other common symptoms of EVD like fever or pain should be treated with 
acetaminophen and opioids. NSAIDs, because of their effect on platelets should 
be avoided [16]. To minimalize hospital acquire complications such as stress ul-
ceration or venous thrombo-embolic disease standard prophylactic should also 
be considered [1].
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We cannot forget that most of the patients with EVD are unable to maintain 
oral intake due to nausea and vomiting and are in risk for malnutrition. In less 
severe cases antiemetic drugs, smaller volume of food and more frequent eating 
may increase tolerance for oral intake. Placement of nasogastric or orogastric 
tube may also be useful. In most severe cases, after 8 days of unsuccessful en-
teral nutrition, total parenteral nutrition is needed until adequate oral intake is 
possible [16, 23].
Giving that Ebola is highly contagious through direct contact with bodily flu-
ids, contaminated objects and possibility of its aerosol route of infection isn’t 
definitely excluded it is crucial to reduce the risk of human-to-human transmis-
sion. Isolation of the infected patients, protective cloths and equipment, control 
protocols, proper waste and samples management are essential to protect medical 
personnel and prevent spreading of the infection [1].
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